209 related articles for article (PubMed ID: 33350072)
61. Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer.
Cui S; Zhang W; Xiong L; Pan F; Niu Y; Chu T; Wang H; Zhao Y; Jiang L
Oncotarget; 2017 Jan; 8(2):2771-2780. PubMed ID: 27926526
[TBL] [Abstract][Full Text] [Related]
62. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
63. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study.
Conde E; Hernandez S; Martinez R; Angulo B; De Castro J; Collazo-Lorduy A; Jimenez B; Muriel A; Mate JL; Moran T; Aranda I; Massuti B; Rojo F; Domine M; Sansano I; Garcia F; Felip E; Mancheño N; Juan O; Sanz J; Gonzalez-Larriba JL; Atienza-Cuevas L; Arriola-Arellano E; Abdulkader I; Garcia-Gonzalez J; Camacho C; Rodriguez-Abreu D; Teixido C; Reguart N; Gonzalez-Piñeiro A; Lazaro-Quintela M; Lozano MD; Gurpide A; Gomez-Roman J; Lopez-Brea M; Pijuan L; Salido M; Arriola E; Company A; Insa A; Esteban-Rodriguez I; Saiz M; Azkona E; Alvarez R; Artal A; Plaza ML; Aguiar D; Enguita AB; Benito A; Paz-Ares L; Garrido P; Lopez-Rios F
J Thorac Oncol; 2019 Dec; 14(12):2120-2132. PubMed ID: 31349061
[TBL] [Abstract][Full Text] [Related]
64. Detection of Targetable Genetic Alterations in Korean Lung Cancer Patients: A Comparison Study of Single-Gene Assays and Targeted Next-Generation Sequencing.
Park E; Shim HS
Cancer Res Treat; 2020 Apr; 52(2):543-551. PubMed ID: 31726498
[TBL] [Abstract][Full Text] [Related]
65. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract][Full Text] [Related]
66. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
[TBL] [Abstract][Full Text] [Related]
67. Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases.
Volckmar AL; Leichsenring J; Kirchner M; Christopoulos P; Neumann O; Budczies J; Morais de Oliveira CM; Rempel E; Buchhalter I; Brandt R; Allgäuer M; Talla SB; von Winterfeld M; Herpel E; Goeppert B; Lier A; Winter H; Brummer T; Fröhling S; Faehling M; Fischer JR; Heußel CP; Herth F; Lasitschka F; Schirmacher P; Thomas M; Endris V; Penzel R; Stenzinger A
Int J Cancer; 2019 Aug; 145(3):649-661. PubMed ID: 30653256
[TBL] [Abstract][Full Text] [Related]
68. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.
Tuononen K; Mäki-Nevala S; Sarhadi VK; Wirtanen A; Rönty M; Salmenkivi K; Andrews JM; Telaranta-Keerie AI; Hannula S; Lagström S; Ellonen P; Knuuttila A; Knuutila S
Genes Chromosomes Cancer; 2013 May; 52(5):503-11. PubMed ID: 23362162
[TBL] [Abstract][Full Text] [Related]
69. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
[TBL] [Abstract][Full Text] [Related]
70. Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers.
Xia P; Zhang L; Li P; Liu E; Li W; Zhang J; Li H; Su X; Jiang G
J Transl Med; 2021 Jul; 19(1):308. PubMed ID: 34271921
[TBL] [Abstract][Full Text] [Related]
71. Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies; a retrospective study.
Kogo M; Fujimoto D; Hosoya K; Nagata K; Nakagawa A; Tachikawa R; Yamashita D; Kitamura Y; Imai Y; Tomii K
BMC Cancer; 2020 Feb; 20(1):104. PubMed ID: 32028905
[TBL] [Abstract][Full Text] [Related]
72. Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?
Ou SH; Soo RA; Kubo A; Kawaguchi T; Ahn MJ
Front Oncol; 2014; 4():58. PubMed ID: 24744988
[TBL] [Abstract][Full Text] [Related]
73. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma.
Rachiglio AM; Esposito Abate R; Sacco A; Pasquale R; Fenizia F; Lambiase M; Morabito A; Montanino A; Rocco G; Romano C; Nappi A; Iaffaioli RV; Tatangelo F; Botti G; Ciardiello F; Maiello MR; De Luca A; Normanno N
Oncotarget; 2016 Oct; 7(41):66595-66605. PubMed ID: 27448974
[TBL] [Abstract][Full Text] [Related]
74. Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer.
Yoon SH; Choi YD; Oh IJ; Kim KS; Choi H; Chang J; Shin HJ; Park CK; Kim YC
Cancer Res Treat; 2015 Oct; 47(4):661-9. PubMed ID: 25715768
[TBL] [Abstract][Full Text] [Related]
75. Clinicopathological Features of ALK Expression in 9889 Cases of Non-small-Cell Lung Cancer and Genomic Rearrangements Identified by Capture-Based Next-Generation Sequencing: A Chinese Retrospective Analysis.
Zhao R; Zhang J; Han Y; Shao J; Zhu L; Xiang C; Zhang Q; Teng H; Qin G; Zhao L; Ye M; Zhao J; Ding W
Mol Diagn Ther; 2019 Jun; 23(3):395-405. PubMed ID: 30840206
[TBL] [Abstract][Full Text] [Related]
76. Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practice-A new approach to improve personalized translational research.
Vavalà T; Monica V; Lo Iacono M; Mele T; Busso S; Righi L; Papotti M; Scagliotti GV; Novello S
Lung Cancer; 2017 May; 107():84-90. PubMed ID: 27346245
[TBL] [Abstract][Full Text] [Related]
77. Evaluation of appropriate conditions for Oncomine DxTT testing of FFPE specimens for driver gene alterations in non-small cell lung cancer.
Iwama E; Yamamoto H; Okubo F; Ijichi K; Ibusuki R; Shiaraishi Y; Yoneshima Y; Tanaka K; Oda Y; Okamoto I
Thorac Cancer; 2023 Aug; 14(23):2288-2296. PubMed ID: 37345344
[TBL] [Abstract][Full Text] [Related]
78. Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer.
Rozenblum AB; Ilouze M; Dudnik E; Dvir A; Soussan-Gutman L; Geva S; Peled N
J Thorac Oncol; 2017 Feb; 12(2):258-268. PubMed ID: 27865871
[TBL] [Abstract][Full Text] [Related]
79. Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multidisciplinary group.
Malapelle U; Donne AD; Pagni F; Fraggetta F; Rocco EG; Pasello G; Perrone G; Pepe F; Vatrano S; Pignata S; Pinto C; Pruneri G; Russo A; Soto Parra HJ; Vallone S; Marchetti A; Troncone G; Novello S
Crit Rev Oncol Hematol; 2024 Jan; 193():104217. PubMed ID: 38040072
[TBL] [Abstract][Full Text] [Related]
80. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS
Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]